NYSE:NVOPharmaceuticals
Novo Nordisk Voucher Win Meets Rising Scrutiny Of FDA Review Program
Novo Nordisk (NYSE:NVO) has received an FDA National Priority Voucher tied to a higher dose of its obesity drug Wegovy.
This is the fourth such voucher granted for the higher dose version, marking another key regulatory step for the product.
The decision comes as the FDA prepares a June public meeting to review and discuss the controversial priority voucher program.
Lawmakers have called for more transparency around how these vouchers are awarded and used, which could influence future...